ENMD-0995 (S 3-APG), a novel thalidomide analogue, has promising clinical activity for patients with relapsed refractory multiple myeloma. Preliminary results of a phase I clinical trial.

被引：0
|
作者：
Lacy, MQ
Dispenzieri, A
Gertz, MA
Wilzig, TE
Greipp, PR
Fonseca, R
Lust, JA
Kumar, S
Zeldenrust, S
Kyle, RA
Snow, D
Hayman, SR
Sidor, CF
Treston, AM
Zeldis, JB
Rajkumar, SV
机构：
[1] Celgene Corp, Warren, NJ USA
[2] Entremed Inc, Rockford, IL USA
[3] Mayo Clin, Rochester, MN USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1654
引用
收藏
页码：453A / 453A
页数：1
相关论文
共 50 条
  • [41] Coagulation disorders during CRS of a BCMA targeted CAR T cell therapy in relapsed/refractory multiple myeloma: Periodic results of a phase I clinical trial
    Shao, Mi
    Hu, Yongxian
    Xu, Huijun
    Zhang, Yanlei
    Cui, Jiazhen
    Huang, He
    BONE MARROW TRANSPLANTATION, 2019, 54 : 45 - 46
  • [42] The Novel KSP Inhibitor ARRY-520 Demonstrates Single-Agent Activity in Refractory Myeloma: Results From a Phase 2 Trial in Patients with Relapsed/Refractory Multiple Myeloma (MM)
    Lonial, Sagar
    Cohen, Adam
    Zonder, Jeffrey
    Benzinger, William I.
    Kaufman, Jonathan L.
    Orlowski, Robert Z.
    Harvey, R. Donald
    Alexanian, Raymond
    Thomas, Sheeba K.
    Weber, Donna
    Walker, Duncan
    Hilder, Brandi
    Ptazynski, Ann
    Shah, Jatin J.
    BLOOD, 2011, 118 (21) : 1266 - 1266
  • [43] A multicenter phase I/II trial of perifosine (KRX-0401) + bortezomib in relapsed and refractory multiple myeloma patients previously treated wth bortezomib: Preliminary results
    Richardson, P. G.
    Jakubowiak, A.
    Wolf, J.
    Krishnan, A.
    Lonial, S.
    Ghobrial, I.
    Facon, T.
    Colson, K.
    Kendall, T.
    Leister, C.
    Martineau, B.
    Hideshima, T.
    Sportelli, P.
    Birch, R.
    Henderson, I. C.
    Anderson, K.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 155 - 156
  • [44] GLS-010, a novel anti-PD-1 mAb in Chinese patients with relapsed or refractory classical Hodgkin's lymphoma: Preliminary result of a phase II clinical trial.
    Song, Yuqin
    Zhu, Jun
    Lin, Ningning
    Zhang, Chen
    Zhang, Mingzhi
    Bai, Hai
    Cui, Jie
    Liu, Hui
    Ke, Xiaoyan
    Jiang, Yongsheng
    Zhang, Zhihui
    Zhang, Ying
    Liu, Lihong
    Zang, Aimin
    Chen, Chris
    Li, Jing
    Du, Hong
    Meng, Baotong
    Xu, Kehui
    Meng, Haijin
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [45] Efficacy and Safety of Chidamide Combined with Thalidomide, Cyclophosphamide, and Dexamethasone (TC2D) As a Novel Oral Quadruplet Regimen for the Treatment of Relapsed/Refractory Multiple Myeloma: Initial Results of a Phase IIa, Multicenter Clinical Trial
    Li, Yi
    He, Jingsong
    Han, Xiaoyan
    Zheng, Gaofeng
    Zhang, Enfan
    Chen, Qingxiao
    He, Donghua
    Zhao, Yi
    Fu, Jiaping
    Shou, Lihong
    Jiang, Wenhua
    Jiang, Wei
    Qian, Shenxian
    Hu, Huixian
    Huang, He
    Cai, Zhen
    BLOOD, 2021, 138
  • [46] Novel AKT Inhibitor GSK2110183 Shows Favorable Safety, Pharmacokinetics, and Clinical Activity in Multiple Myeloma. Preliminary Results From a Phase I First-Time-In-Human Study
    Spencer, Andrew
    Yoon, Sung-Soo
    Harrison, Simon J.
    Morris, Shannon
    Smith, Deborah
    Freedman, Steven J.
    Brigandi, Richard
    Oliff, Allen
    Opalinska, Joanna B.
    Chen, Christine
    BLOOD, 2011, 118 (21) : 808 - 808
  • [47] A novel BCMA CAR-T-cell therapy with optimized human scFv for treatment of relapsed/refractory multiple myeloma: results from phase I clinical trials
    Yang, Min
    Zhang, Wenhao
    Yu, Kang
    Wang, Peng
    Jiang, Hua
    Chen, Linjun
    Meng, Haitao
    Weng, Yiqin
    Tao, Rong
    Huang, Xin
    Xing, Chongyun
    Wang, Huamao
    Wan, Jiangbo
    Wang, Shasha
    Dai, Lihui
    Hendrix, Amanda Y.
    Xiao, Jun
    Wang, Wei
    Ma, Hong
    Hao, Siguo
    Jin, Jie
    Li, Zonghai
    Jiang, Songfu
    HAEMATOLOGICA, 2022, 107 (08) : 1960 - 1965
  • [48] Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical Trial
    Mailankody, Sham
    Ghosh, Arnab
    Staehr, Mette
    Purdon, Terence J.
    Roshal, Mikhail
    Halton, Elizabeth
    Diamonte, Claudia
    Pineda, John
    Anant, Pavan
    Bernal, Yvette
    Wills, Analisa
    Korde, Neha
    Lendvai, Nikoletta
    Lesokhin, Alexander M.
    Hassoun, Hani
    Hultcrantz, Malin
    Landau, Heather J.
    Shah, Gunjan L.
    Scordo, Michael
    Chung, David J.
    Lahoud, Oscar B.
    Khattar, Pallavi
    de larrea, Carlos Fernandez
    Gao, Qi
    Jungbluth, Achim
    Park, Jae H.
    Curran, Kevin J.
    Sauter, Craig S.
    Palomba, Maria Lia
    Senechal, Brigitte
    Wang, Xiuyan
    Dogan, Ahmet
    Giralt, Sergio
    Riviere, Isabelle
    Landgren, Ola
    Brentjens, Renier J.
    Smith, Eric L.
    BLOOD, 2018, 132
  • [49] Lenalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of a non-interventional study and comparison with the pivotal phase 3 clinical trials
    Knauf, Wolfgang
    Aldaoud, Ali
    Losem, Christoph
    Mittermueller, Johann
    Neise, Michael
    Niemeier, Beate
    Harde, Johanna
    Trarbach, Tanja
    Potthoff, Karin
    LEUKEMIA RESEARCH, 2018, 68 : 90 - 97
  • [50] BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity In a Phase I Study in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma
    Jagannath, Sundar
    Chanan-Khan, Asher A.
    Heffner, Leonard T.
    Avigan, David
    Lutz, Robert J.
    Uherek, Christoph
    Osterroth, Frank
    Ruehle, Markus
    Haeder, Thomas
    Niemann, Gabriele
    Wartenberg-Demand, Andrea
    Munshi, Nikhil C.
    Anderson, Kenneth C.
    BLOOD, 2010, 116 (21) : 1262 - 1262
12345